Biohaven Ltd.
BHVNHealthcareNASDAQBiotechnology · Last scanned May 28, 2026
Scan Results
Daily timeframe1 of 4 indicators bullish as of May 27
Part of the healthcare sector, Biohaven Ltd. (BHVN) is listed under Biotechnology. With a market capitalization of $1.70B, it sits in small-cap territory. It develops BHV-1300, which is in Phase 2 clinical trial to treat Graves' disease and rheumatoid arthritis; BHV-1400 that is in Phase 2 clinical trial for treating IgA nephropathy; BHV-1600, which is in Phase 1 clinical trial for the treatment of peripartum cardiomyopathy; BHV-8000 that is in Phase 3 clinical trial for treating Parkinson's disease; Opakalim, which is in Phase 3 clinical trial for the treatment of focal epilepsy; BHV-2100 that is in Phase 2 clinical trial for the treatment of pain disorders; and BHV-2000, which is in Phase 2 clinical trial for treating obesity.
Market Cap
$1.70B
Beta
3.31
P/E (TTM)
—
P/E (Fwd)
-5.78
EPS (TTM)
$-5.57
EPS (Fwd)
$-1.95
ROE
-333.0%
ROA
-83.4%
Cash
$347.8M
Total Debt
$286.2M
Free CF
-$379.4M
52W Change
-23.4%
Annual Financials
Cash vs Debt
With $347.8M in cash and $286.2M in debt, BHVN maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. Free cash flow is running at -$379.4M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. Return on equity stands at -333.0%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits.
A beta of 3.31 means BHVN is more volatile than average. Investors should be prepared for wider price swings relative to broader indices. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Biohaven Ltd. and its sector.